跳至主要内容
临床试验/JPRN-jRCTs041180125
JPRN-jRCTs041180125已完成3 期

The efficacy of Zonisamide for BPSD in Dementia with Lewy bodies - The efficacy of Zonisamide for BPSD in Dementia with Lewy bodies

Washimi Yukihiko0 个研究点目标入组 25 人开始时间: 2019年3月23日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
25

研究概览

简要总结

The results of the present study showed no trend for improvement in the BPSD of DLB with zonisamide, which was seen in our exploratory study, based on the amount of change in NPI after 2 and 4 weeks, and zonisamide was not shown to be effective against the BPSD of DLB.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 55age old 至 <= 84age old(—)
性别
All

入选标准

  • 1 Probable DLB with the criteria of DLB workshop 2005
  • 2 BPSD is present on NPI
  • 3 MMSE score 10 26
  • 4 WBC platelet Serum AST ALT ALP GTP level should be in normal range
  • 5 Have a study partner able to provide an independent evaluation of functioning
  • 6 Agreement to sign an informed consent

排除标准

  • 1 Patient with non DLB.
  • 2 No focal lesion exists in brain MRI.
  • 3 Has current serious illness, psychiatric problem or drug abuse.
  • 4 Those who have used Zonisamide over before.
  • 5 Those who have joined any clinical trial within 3 month.
  • 6 Those who have received medications that affected the central nervous system within 4 weeks.
  • 7 Dose of chronic medications that affect CNS should be stable for at least 4 weeks before Visit0.
  • 8 Those who are judged inadequate by their doctor.

研究者

发起方
Washimi Yukihiko

相似试验

DLB-Z | 临床试验